[The analytical review of the schemes of the acute radiation disease treatment used in experiment and in clinic].
The analysis of the original sources showed that there are some differences in approaches to radiation injuries treatment used mainly by Russian and foreign researches in their experiments. In Russian radiobiology the main way was the single usage of high molecular substances of different chemical structure and of natural origin soon after radiation exposure. These substances were designated then as cytokine inductors. Foreign researchers investigated in the beginning analogous substances too, but then--recombinant cytokines exclusively. In native radiobiology the urgent (in limits of 2 h) and early (in limits of 6-24 h) pathogenic therapy develops already for a long time. There are preparations, betaleukine (recombinant human interleukine 1 beta) and dezoksinat (degraded DNA), as results of developing the directions. Both have licenses on the administration at radiation accidents. But the issues of various medicaments optimal combinations in a common scheme of early (in first 24 h) medical help remain undefined accurately. The consensus protocol of radiation injuries treatment in clinic consists of the supportive therapy (aseptic conditions, wide antimicrobic antibiotics, thrombocytes and erythrocytes transfusions) and the myelostimulation therapy by cytokine combinations. The hemopoietic stem cells transplantation in cases of severe radiation damages treatment remains under question in the reason of immunological conflict between a host and a graft.
Baranov
A E
AE
Rozhdestvenskiĭ
L M
LM
D054508:Acute Radiation Syndrome / Q000188:drug therapy / Q000628:therapy*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017707:Erythrocyte Transfusion; D006801:Humans; D053583:Interleukin-1beta / Q000627:therapeutic use; D017713:Platelet Transfusion; D011833:Radiation Injuries, Experimental / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D016207:Cytokines; D053583:Interleukin-1beta; D011994:Recombinant Proteins